With Russia being the first candidate to come up with its vaccine (Sputnik-V), there’s a race in the development of vaccine all over the world. Several candidates around the world are progressing towards Phase 3 trials.
With the time frame being reduced for vaccine development, potential risks involved are much higher and the results of human trials are very important for its efficacy.
More than 60,000 people have applied to volunteer for the coronavirus vaccine trials in Moscow and over 700 people have been injected with the coronavirus vaccine, the media reported.
Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.
“Over 60,000 people have signed up as volunteers, several thousand people have passed the required medical tests to be registered as potential candidates for carrying out the tests,” Mayor Sergei Sobyanin was quoted as saying in reports on Sunday.
According to Russian Tass news agency, more than 700 people have been injected with the coronavirus vaccine.
“All of them are feeling good,” Sobyanin said.
The vaccine was developed on a platform that had been used for a number of other vaccines.
The Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories Limited, a global pharmaceutical company headquartered in India, have also agreed to cooperate on clinical trials and distribution of Sputnik V Covid-19 vaccine in India.
“On regulatory approval in India, RDIF shall supply to Dr Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” said a statement from the fund.
The Russian Direct Investment Fund said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.
Earlier this month, letter questioning the reliability of the info introduced within the early-stage trial outcomes of the Russian Covid-19 vaccine, named “Sputnik-V”.
YOU MAY LIKE TO READ: Covid-19: Russian Vaccine Shows Signs Of Antibody Response, Says Lancet Study
Addressing the editor of The Lancet, the worldwide peer-reviewed medical journal during which Moscow’s Gamaleya Institute revealed its early-stage trial outcomes, the scientists stated they noticed patterns within the knowledge that seemed “extremely unlikely”.
The Gamaleya Institute, which developed the vaccine, rejected the criticism.
“The published results are authentic and accurate and were examined by five reviewers at The Lancet,” Denis Logunov, a deputy director at the institute, said in a statement. He said his institute submitted the entire body of raw data on the trial results to The Lancet. “We presented specifically the data that was produced (by the trial), not the data that is supposed to please Italian experts,” Logunov said.